Bioqual, Inc. (BIOQ)

Market Cap	29.07M -26.6%
Revenue (ttm)	42.35M -13.6%
Net Income	-1.24M
EPS	-1.38
Shares Out	894.42K
PE Ratio	n/a
Forward PE	n/a
Dividend	0.50 (1.54%)
Ex-Dividend Date	Oct 7, 2024

Volume	1,272
Open	32.50
Previous Close	32.50
Day's Range	32.50 - 32.50
52-Week Range	32.50 - 43.55
Beta	-0.10
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 18, 2026

About Bioqual

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides contract research services in the areas of AIDS, influenza, respiratory syncytial virus, Coronavirus, malaria, hepatitis, cancer, and other infectious diseases, as well as flavivirus infections, including zika and dengue. It also offers small and large animal models. In addition, the company provides cell-based assays, immunoassay, toxicology and cytotoxicity testing, viral load testing, and ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1981
• Employees: 113
• Stock Exchange: OTCMKTS
• Ticker Symbol: BIOQ

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 20, 2026

Data Sources Report a data error